ClinicalTrials.gg
CompletedNCT02541669Updated Feb 5, 2020Results posted

A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants

A Phase 1 interventional study of TAK-491 and TAK-491 placebo in Healthy Volunteer, sponsored by Takeda. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to assess the pharmacokinetics and safety of single- and multiple-dose of TAK-491 in healthy Chinese participants.

Read the detailed description

The drug being tested in this study is called TAK-491. TAK-491 is being tested to treat people who have hypertension. This study will look at the pharmacokinetics of TAK-491 in Chinese participants who take TAK-491.

The study will enroll approximately 64 participants.

The first 16 enrolled participants have been randomly assigned (by chance, like flipping a coin) to 1 of the 2 treatment groups:

  • TAK-491 40 mg
  • TAK-491 80 mg

All participants will be asked to take 1 tablet at the same time on Day 1 and Day 4 to 10 during the study.

The following 48 randomized participants will be randomly assigned (by chance, like flipping a coin) to 1 of the 3 treatment groups:

  • TAK-491 40 mg
  • TAK-491 80 mg
  • TAK-491 placebo

All participants will be asked to take two tablets at the same time on Day 1 and Day 4 to 10 during the study.

This single-center trial will be conducted in China. The overall time to participate in this study is approximately 52 days. Participants will be admitted in the clinic for the first 12 days, and will be contacted by telephone 14 days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Is a healthy adult male or female of Chinese descent.
  4. Is aged 18 to 45 years, inclusive, at the time of informed consent and first study medication dose.
  5. Has a (BMI) greater than or equal to (>=) 19.0 kilogram per square meter (kg/m\^2) and less than (\<) 24.0 kg/m\^2, inclusive at Screening.
  6. Has clinical laboratory evaluations (including clinical chemistry [fasted for at least 8 hours for the screening assessment], hematology, and complete urinalysis) within the reference range for the testing laboratory, unless the results were deemed by the investigator to be not at Screening and Check-in (Day -1).
  7. Is willing to refrain from strenuous exercise, from 72 hours before Check-in (Day-1) until after Final Visit.
  8. A female of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent throughout the duration of the study and for 30 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days prior to Screening.
  2. Has received TAK-491 in a previous clinical study or as a therapeutic agent.
  3. Is an immediate family member, study site employee, or in a dependant relationship with a study site employee who is involved in the conduct of this study (example, spouse, parent, child, sibling) or may consent under duress.
  4. Has history of uncontrolled, manifestations of metabolic (including diabetes mellitus, hypercholesterolemia, or dyslipidemia), endocrine, hematologic, pulmonary, cardiovascular, gastrointestinal, neurological, rheumatologic, skin and subcutaneous tissue disorders, infectious, hepatic, renal, urologic, immunologic, psychiatric or mood disorders (including any past history of suicide attempt), or a history of lactose intolerance, which may impact the ability of the participant to participate or potentially confound the study results.
  5. Has a known to any component of the formulation of TAK-491 or other AII inhibitors or related compounds.
  6. Has a positive urine drug result for drugs of abuse or breath alcohol test at Screening or Check-in (Day -1).
  7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  8. Has taken any excluded medication, supplements, or food products.
  9. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period.
  10. Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (that is, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis frequent [more than once per week] occurrence of heartburn, or any surgical intervention [example, cholecystectomy]).
  11. Has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Day 1.
  12. Has positive test result for anti- (HIV), anti- virus (HCV) antibodies, or for surface antigen (HBsAg) at Screening.
  13. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in (Day -1). Cotinine test is positive at Screening or Check-in (Day -1).
  14. Has poor peripheral venous access.
  15. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 30 days prior to Day 1.
  16. Has a Screening or Check-in (Day -1) abnormal (clinically significant) (ECG). Entry of any participants with an abnormal (not clinically significant) ECG must be approved, and documented by signature by the principal investigator.
  17. Has abnormal Screening or Check-in (Day -1) laboratory values that suggest a clinically significant underlying disease or participant with the following lab abnormalities: (ALT) and/or aspartate aminotransferase (AST) greater than (>) 1.5 times the .
  18. Has a value \<12 gram per deciliter (g/dL) at Screening.
  19. Has a systolic blood pressure \<110 and >=160 millimeter of Mercury (mmHg) or a diastolic blood pressure \<60 and >=100 mmHg at Screening or Check-in (Day -1).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    TAK-491 40 mg (Open Label)

    TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.

    Drug: TAK-491

  • Experimental
    TAK-491 80 mg (Open-label)

    TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.

    Drug: TAK-491

  • Experimental
    TAK-491 40 mg (Double-blind)

    TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.

    Drug: TAK-491 · Drug: TAK-491 placebo

  • Experimental
    TAK-491 80 mg (Double-blind)

    TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.

    Drug: TAK-491 · Drug: TAK-491 placebo

  • Placebo comparator
    Placebo

    TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.

    Drug: TAK-491 placebo

Interventions

  • TAK-491 tablets

    Also known as: Azilsartan medoxomil, Edarbi

  • DrugTAK-491 placebo

    TAK-491 placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  2. Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10

    Time frame: Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose

  3. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  4. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10

    Time frame: Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose

  5. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  6. AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10

    Time frame: Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose

  7. Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

07

Results

Posted Feb 5, 2020

Participant flow

Participants took part in the study at 1 investigative site in China from 17 November 2015 to 17 March 2017.

Open Label Treatment Period
Participant flow — Open Label Treatment Period
MilestoneOpen Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
Started88000
Completed88000
Not completed00000
Double-Blinded Treatment Period
Participant flow — Double-Blinded Treatment Period
MilestoneOpen Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
Started00161616
Completed00151615
Not completed00101
Withdrew: Withdrawal by subject00101

Outcome measures

PrimaryCmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
nanogram per milliliter (ng/mL)Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 12877 ± 25.06250 ± 20.52444 ± 22.55460 ± 30.4
PrimaryCmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
Time frame:
Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose
Reported as:
Geometric mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
ng/mLOpen Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 103070 ± 4.66019 ± 29.52628 ± 23.36226 ± 19.9
PrimaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Median · hour
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
hourOpen Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 13.03 (2.00 to 6.00)2.50 (2.00 to 4.00)3.00 (2.00 to 6.03)2.50 (1.00 to 6.00)
PrimaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
Time frame:
Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose
Reported as:
Median · hour
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
hourOpen Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 103.00 (1.00 to 4.00)2.52 (2.00 to 6.00)3.49 (1.98 to 5.98)2.00 (1.98 to 6.00)
PrimaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
hour*nanogram per milliliter (h*ng/mL)Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 125905 ± 27.350359 ± 12.123439 ± 22.645698 ± 32.1
PrimaryAUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
Time frame:
Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose
Reported as:
Geometric mean · h*ng/mL
AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
h*ng/mLOpen Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1025087 ± 21.545320 ± 14.721872 ± 19.147993 ± 31.8
PrimaryTerminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Geometric mean · hour
Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
hourOpen Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 111.18 ± 19.410.18 ± 24.111.12 ± 16.911.10 ± 18.9

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Day 40). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label: TAK-491 40 mg0/8 (0%)0/8 (0%)4/8 (50%)
Open Label: TAK-491 80 mg0/8 (0%)0/8 (0%)4/8 (50%)
Double-blind: Placebo0/16 (0%)0/16 (0%)6/16 (37.5%)
Double-blind: TAK-491 40 mg0/16 (0%)0/16 (0%)4/16 (25%)
Double-blind: TAK-491 80 mg0/16 (0%)0/16 (0%)10/16 (62.5%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventOpen Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mg
Alanine aminotransferase increasedInvestigations0/82/81/160/164/16
Aspartate aminotransferase increasedInvestigations0/80/81/160/164/16
Transaminases increasedInvestigations2/82/80/160/160/16
Blood triglycerides increasedInvestigations0/80/81/161/163/16
Blood creatine phosphokinase increasedInvestigations1/80/80/160/162/16
DizzinessNervous system disorders1/80/80/162/160/16
VertigoEar and labyrinth disorders0/80/80/161/160/16
AstheniaGeneral disorders0/80/80/160/161/16
NasopharyngitisInfections and infestations0/80/81/160/161/16
Gastrointestinal viral infectionInfections and infestations0/80/80/160/161/16

Baseline characteristics

The randomized set included all participants who were randomized.

Age, Continuous
Age, Continuous(years)Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mgTotal
Mean28.8 ± 4.4030.3 ± 4.9833.0 ± 5.0727.4 ± 4.1929.7 ± 5.6329.9 ± 5.19
Sex: Female, Male
Sex: Female, Male(Participants)Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mgTotal
Female3311311
Male5515151353
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mgTotal
American Indian or Alaska Native000000
Asian8816161664
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mgTotal
China8816161664
Height
Height(centimeter (cm))Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mgTotal
Mean169.9 ± 6.66165.3 ± 6.36171.0 ± 6.07170.4 ± 5.80171.9 ± 6.75170.2 ± 6.41
Weight
Weight(kilogram (kg))Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mgTotal
Mean66.23 ± 4.78559.83 ± 4.95164.09 ± 6.01264.79 ± 7.91665.69 ± 6.93464.40 ± 6.619
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mgTotal
Mean22.96 ± 1.28921.94 ± 1.70721.89 ± 1.14322.23 ± 1.70322.16 ± 1.10922.18 ± 1.382
Smoking classification
Smoking classification(Participants)Open Label: TAK-491 40 mgOpen Label: TAK-491 80 mgDouble-blind: PlaceboDouble-blind: TAK-491 40 mgDouble-blind: TAK-491 80 mgTotal
Never smoked8814141357
Current smoker000000
Ex-smoker002237

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Beijing, Beijing,P.R., China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Mar 2017, 15 months.

Results were first posted in Feb 2020, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2015
First posted
Sep 4, 2015
StartActual
Nov 20, 2015
Primary completionActual
Mar 17, 2017
CompletionActual
Mar 17, 2017
Results first posted
Feb 5, 2020
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02541669
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 4, 2015
Start date
Nov 20, 2015
Primary completion
Mar 17, 2017
Completion
Mar 17, 2017
Results posted
Feb 5, 2020
Last update
Feb 5, 2020

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion